The New England Journal of Medicine has now given us randomized trial evidence for a question long guided more by extrapolation than by direct proof: in patients with established atherosclerotic cardiovascular disease, targeting LDL cholesterol to

Elegant trial, practical message: when risk is high, lower may truly be better. 🫀📉🎯 Journal: New England Journal of Medicine.